Feraccru® granted major extension to approval in Switzerland

24 Apr 2019

Shield Therapeutics plc, announces that the Swiss Agency for Therapeutic Products (Swissmedic) has approved a major extension of the approved indication for Feraccru® to now include treatment of all adults with iron deficiency (ID) with or without anaemia. For further details click here.

Back to news